Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trialEuropean Heart Journal, 2015
- Marfan Sartan: a randomized, double-blind, placebo-controlled trialEuropean Heart Journal, 2015
- Atenolol versus Losartan in Children and Young Adults with Marfan's SyndromeNew England Journal of Medicine, 2014
- 2014 ESC Guidelines on the diagnosis and treatment of aortic diseasesEuropean Heart Journal, 2014
- Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trialEuropean Heart Journal, 2013
- Circulating Transforming Growth Factor-β in Marfan SyndromeCirculation, 2009
- Angiotensin II Blockade and Aortic-Root Dilation in Marfan's SyndromeNew England Journal of Medicine, 2008
- The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: A meta-analysisInternational Journal of Cardiology, 2007
- Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndromeNature Genetics, 2003
- Progression of Aortic Dilatation and the Benefit of Long-Term β-Adrenergic Blockade in Marfan's SyndromeNew England Journal of Medicine, 1994